This is a prescription medicine. A prescription is required from your veterinarian before we can supply this product. Please ensure that you have read the "How to Order" page before ordering this item.
All of our products are APVMA or TGA approved and identical to those used by your veterinarian. Please call or email us if you have any queries about any of the products on our site.
|Drug Name and Strength||Carprofen 50mg|
|Indication||Relief of pain and inflammation in dogs.|
|Contraindications||Administration to dogs exhibiting previous hypersensitivity to carprofen, or to dogs with cardiac, hepatic or renal disease, or where there is evidence of a blood dyscrasia. Administration to dehydrated, hypovolaemic or hypotensive animals is associated with a potential risk of increased renal toxicity.Concurrent administration with other NSAIDs, steroids or potential nephrotoxic drugs within 24 hours of each other. If changing anti-inflammatory products, take into account the pharmacokinetic properties of the drugs used previously when considering the delay period between the individual drugs.Safe use in pregnant and lactating bitches and dogs used for breeding purposes has not been established. In the absence of any specific studies in pregnant animals, such use is contraindicated.|
|Actions||Pharmacology Carprofen is a non-narcotic, nonsteroidal, anti-inflammatory drug with characteristic analgesic and antipyretic activity. As with other NSAIDs (nonsteroidal anti-inflammatory drugs), the exact mode of action of carprofen has not been established. However, inhibition of prostaglandin synthesis accounts for at least part of its mechanism of action. Carprofen is a moderately potent inhibitor of phospholipase A2 and a reversible inhibitor of cyclooxygenase.Pharmacokinetics Carprofen is rapidly and nearly completely absorbed when administered orally. Peak blood plasma concentrations are achieved in one to three hours after oral administration to dogs. The mean terminal half-life is approximately eight hours after single oral doses. After a single intravenous bolus dose of 100 mg, the mean elimination half-life was approximately 11.7 hours in the dog.Carprofen is more than 99% bound to plasma protein and exhibits a very small volume of distribution. It is eliminated in the dog primarily by biotransformation in the liver, followed by rapid excretion of the resulting metabolites in the faeces (70 to 80%) and urine (10 to 20%).Mean plasma carprofen concentrations are similar for oral liquid and tablet forms given as single oral doses of carprofen 4 mg/kg bodyweight. Data was generated in 12 dogs in a blinded, randomised cross over trial with a 14 day washout between dosing periods, using Rimadyl Tablets and Prolet Oral Liquid.|
|Precautions||All dogs should undergo a thorough clinical examination and appropriate laboratory tests to establish haematological and serum biochemical baseline data before introduction of NSAID therapy. During extended administration, appropriate re-evaluation and laboratory tests should be undertaken periodically.Use in animals less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such animals may require a reduced dosage and careful clinical management.NSAIDs can cause inhibition of phagocytosis, so treatment of inflammatory conditions associated with bacterial infection should be accompanied by appropriate antimicrobial therapy.Use with caution in dogs with bleeding disorders (e.g. Von Willebrand's disease), as safety has not been established in dogs with these disorders.As a class, cyclooxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Effects may result from decreased prostaglandin production, and inhibition of the enzyme cyclooxygenase, which is responsible for the formation of prostaglandins from arachidonic acid. When NSAIDs inhibit the production of prostaglandins that cause inflammation they may also inhibit production of those prostaglandins which maintain homeostatic function. These inhibitory effects may result in clinically significant disease in animals with underlying or pre-existing disease more often than in healthy patients. Sensitivity to drug-associated adverse effects varies with the individual patient. NSAID therapy could unmask occult disease undiagnosed due to the absence of clinical signs.Disposal Dispose of empty container by wrapping with paper and putting in garbage.|
|Dosage and Administration||2 to 4 mg/kg bodyweight/day. Dose, frequency and duration of treatment will be dependent on clinical response of the condition under treatment. Initial therapy at 4 mg/kg bodyweight/day given in two equally divided doses is generally recommended. Subject to clinical response, the dose may be reduced to 2 mg/kg bodyweight/day administered as a once daily dose. Liquid. 1 to 2 mL/10 kg bodyweight/day. Calculate dose and withdraw from bottle using a graduated syringe. Contents of syringe can then be mixed with food for ease of administration, or directly inserted into dog's mouth and gently squeezed on the back of the tongue, taking care to avoid aspiration. The syringe can be reused provided it is cleaned and dried between uses. Tablets. 2 to 4 mg/kg bodyweight/day.|
|Storage||Store liquid and tablets below 30°C (room temperature) out of direct sunlight. Keep tablets in a dry place.|
|MSDS (external link)||Prolet 50mg Tablets MSDS|
|Label (external link)||Prolet 50mg Tablets Label|
|Manufacturer||Jurox Pty Limited|